Back To Top

Tangs Clinic

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form
12
Jul

A Review of Health Outcomes in Patients with Psoriasis

Posted by on in Skin Matters
  • Font size: Larger Smaller
  • Hits: 8710
  • 0 Comments
  • Print
Pearce and colleagues110 examined the cost-effectiveness of psoriasis treatments over a 12-week period comparing methotrexate, acitretin, cyclosporine, narrow band UV-B, PUVA, etanercept, and efalizumab. The total cost per completed treatment regimen was calculated based on drug acquisition costs, dosing and cost of physician visits, laboratory testing, phototherapy treatment charges, liver biopsy, and infusions charges. The total cost for a 12-week completed treatment was $3921 for PUVA, $2658 for UV-B, $436 for methotrexate, $1419 for acitretin, $2464 for cyclosporine, $4299 for efalizumab, and $7993 for etanercept. The cost-effectiveness for a 12-week completed treatment was $623 for methotrexate, $2729 for acitretin, $3692 for narrow band UV-B, $4668 for PUVA, $16,323 for etanercept, and $17,196 for efalizumab.

A Review of Health Outcomes in Patients with Psoriasis

Reference:
Li Kai & Armstrong April W. (2012). A Review of Health Outcomes in Patients with Psoriasis. Dermatologic Clinics. Volume 30, Issue 1, Pages 61-72, January 2012

Rate this blog entry:
Tagged in: Psoriasis

Comments

  • No comments made yet. Be the first to submit a comment

Leave your comment

Guest Wednesday, 14 November 2018